- Home
- NVS vs MRK Comparison
NVS vs MRK Comparison
Compare NVS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- MRK
- Stock Information
- Founded
- NVS 1895
- MRK 2000
- Country
- NVS Switzerland
- MRK United States
- Employees
- NVS N/A
- MRK N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- MRK Health Care
- Exchange
- NVS Nasdaq
- MRK Nasdaq
- Market Cap
- NVS 254.8B
- MRK 218.8B
- IPO Year
- NVS 1991
- MRK N/A
- Fundamental
- Price
- NVS $122.61
- MRK $86.28
- Analyst Decision
- NVS Hold
- MRK Buy
- Analyst Count
- NVS 5
- MRK 15
- Target Price
- NVS $119.00
- MRK $105.14
- AVG Volume (30 Days)
- NVS 1.8M
- MRK 10.0M
- Earning Date
- NVS 10-28-2025
- MRK 10-30-2025
- Dividend Yield
- NVS 2.13%
- MRK 3.74%
- EPS Growth
- NVS N/A
- MRK 20.41
- EPS
- NVS 7.30
- MRK 6.49
- Revenue
- NVS $56,372,000,000.00
- MRK $63,616,000,000.00
- Revenue This Year
- NVS $9.06
- MRK $1.76
- Revenue Next Year
- NVS $2.54
- MRK $5.11
- P/E Ratio
- NVS $16.69
- MRK $13.35
- Revenue Growth
- NVS 12.88
- MRK 1.82
- 52 Week Low
- NVS $96.06
- MRK $73.31
- 52 Week High
- NVS $133.55
- MRK $105.11
- Technical
- Relative Strength Index (RSI)
- NVS 32.08
- MRK 42.56
- Support Level
- NVS $121.57
- MRK $86.91
- Resistance Level
- NVS $132.33
- MRK $88.30
- Average True Range (ATR)
- NVS 1.64
- MRK 1.43
- MACD
- NVS -1.33
- MRK -0.25
- Stochastic Oscillator
- NVS 5.98
- MRK 5.90
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).